BIAF News
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing...
PR Newswire
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing...
PR Newswire
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its previously announced registered direct offering of shares of common stock (or...
Business Wire
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct...
PR Newswire
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into a definitive agreement with an institutional investor to sell shares of common...
Business Wire
These Stocks are Lighting it Up
These names stand out for very different reasons: NeOnc Technologies (NASDAQ:NTHI), Hyperfine (NASDAQ:HYPR), bioAffinity Technologies (NASDAQ:BIAF), Profound Medical (NASDAQ:PROF), Wolfspeed (NYSE: WOLF) and Sunshine Biopharma (NASDAQ:SBFM).
24-7 Market News
bioAffinity’s Lung-Cancer AI Gets Japanese Patent Boost as CyPath Lung Sales Surge
bioAffinity Technologies (NASDAQ:BIAF) is adding another layer of protection around its most important commercial asset just as adoption of its CyPath Lung diagnostic is accelerating.
24-7 Market News
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath Lung and AI-Built Algorithm
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Notice of Allowance indicating its intention to...
Business Wire
bioAffinity Technologies Reports Over 100% Growth in CyPath Lung Sales Through Third Quarter 2026
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that sales of its CyPath Lung test for lung cancer increased more than 100% through the third quarter of...
Business Wire
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, is taking significant steps toward bringing its lung cancer test to the veterans who need it. This week, bioAffinity and...
Business Wire
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath Lung at NAVREF 2026 Annual Conference
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced it is presenting two posters highlighting its noninvasive lung cancer diagnostic, CyPath Lung, in...
Business Wire